Safety and administration of treatment with botulinum neurotoxin for sialorrhoea in ALS patients: Review of the literature and a proposal for tailored treatment

Morten Gersel Stokholm, Carsten Bisgård, Ole Jakob Vilholm

Publikation: Bidrag til tidsskriftReviewForskningpeer review

Resumé

Botulinum neurotoxin (BoNT) is a second-line treatment of sialorrhoea in ALS (amyotrophic lateral sclerosis) patients. This article is a review of the published literature concerning safety and administration of this treatment to ALS patients. A PubMed search was performed. All original publications on BoNT treatment of sialorrhoea in ALS patients were included in the review. Only a few adverse events were observed concerning treatment with BoNT. The studies performed to date have applied different treatment strategies with different dosages. In conclusion, BoNT treatment for sialorrhoea in ALS patients is safe with few adverse effects. The authors advocate for the implementation of a personalized treatment strategy. Special precautions must be taken when patients do not have the assistance of a ventilator and a feeding tube.
OriginalsprogEngelsk
TidsskriftAmyotrophic Lateral Sclerosis
Vol/bind14
Udgave nummer7-8
Sider (fra-til)516-20
ISSN1748-2968
DOI
StatusUdgivet - 2013

Fingeraftryk

Sialorrhea
Neurotoxins
Safety
Enteral Nutrition
Mechanical Ventilators
PubMed
Publications

Citer dette

@article{ccf39ebf1ded45fd912e31fbeab7500a,
title = "Safety and administration of treatment with botulinum neurotoxin for sialorrhoea in ALS patients: Review of the literature and a proposal for tailored treatment",
abstract = "Botulinum neurotoxin (BoNT) is a second-line treatment of sialorrhoea in ALS (amyotrophic lateral sclerosis) patients. This article is a review of the published literature concerning safety and administration of this treatment to ALS patients. A PubMed search was performed. All original publications on BoNT treatment of sialorrhoea in ALS patients were included in the review. Only a few adverse events were observed concerning treatment with BoNT. The studies performed to date have applied different treatment strategies with different dosages. In conclusion, BoNT treatment for sialorrhoea in ALS patients is safe with few adverse effects. The authors advocate for the implementation of a personalized treatment strategy. Special precautions must be taken when patients do not have the assistance of a ventilator and a feeding tube.",
author = "Stokholm, {Morten Gersel} and Carsten Bisg{\aa}rd and Vilholm, {Ole Jakob}",
year = "2013",
doi = "10.3109/21678421.2013.830312",
language = "English",
volume = "14",
pages = "516--20",
journal = "Amyotrophic Lateral Sclerosis",
issn = "1748-2968",
publisher = "Taylor & Francis",
number = "7-8",

}

Safety and administration of treatment with botulinum neurotoxin for sialorrhoea in ALS patients : Review of the literature and a proposal for tailored treatment. / Stokholm, Morten Gersel; Bisgård, Carsten; Vilholm, Ole Jakob.

I: Amyotrophic Lateral Sclerosis, Bind 14, Nr. 7-8, 2013, s. 516-20.

Publikation: Bidrag til tidsskriftReviewForskningpeer review

TY - JOUR

T1 - Safety and administration of treatment with botulinum neurotoxin for sialorrhoea in ALS patients

T2 - Review of the literature and a proposal for tailored treatment

AU - Stokholm, Morten Gersel

AU - Bisgård, Carsten

AU - Vilholm, Ole Jakob

PY - 2013

Y1 - 2013

N2 - Botulinum neurotoxin (BoNT) is a second-line treatment of sialorrhoea in ALS (amyotrophic lateral sclerosis) patients. This article is a review of the published literature concerning safety and administration of this treatment to ALS patients. A PubMed search was performed. All original publications on BoNT treatment of sialorrhoea in ALS patients were included in the review. Only a few adverse events were observed concerning treatment with BoNT. The studies performed to date have applied different treatment strategies with different dosages. In conclusion, BoNT treatment for sialorrhoea in ALS patients is safe with few adverse effects. The authors advocate for the implementation of a personalized treatment strategy. Special precautions must be taken when patients do not have the assistance of a ventilator and a feeding tube.

AB - Botulinum neurotoxin (BoNT) is a second-line treatment of sialorrhoea in ALS (amyotrophic lateral sclerosis) patients. This article is a review of the published literature concerning safety and administration of this treatment to ALS patients. A PubMed search was performed. All original publications on BoNT treatment of sialorrhoea in ALS patients were included in the review. Only a few adverse events were observed concerning treatment with BoNT. The studies performed to date have applied different treatment strategies with different dosages. In conclusion, BoNT treatment for sialorrhoea in ALS patients is safe with few adverse effects. The authors advocate for the implementation of a personalized treatment strategy. Special precautions must be taken when patients do not have the assistance of a ventilator and a feeding tube.

U2 - 10.3109/21678421.2013.830312

DO - 10.3109/21678421.2013.830312

M3 - Review

C2 - 23984863

VL - 14

SP - 516

EP - 520

JO - Amyotrophic Lateral Sclerosis

JF - Amyotrophic Lateral Sclerosis

SN - 1748-2968

IS - 7-8

ER -